Printer Friendly

Influence of PON1 polymorphisms on the association between serum paraoxonase 1 and homocysteinemia in a general population.

To the Editor:

Homocysteine (Hcy)-induced vascular impairment may be partially mediated by the production of Hcy thiolactone (HTL). This compound acylates side-chain lysine groups in proteins and alters protein structure and function. HTL is formed under conditions of high Hcy resulting from insufficient remethylation of Hcy to methionine; however, HTL is not a reliable marker of plasma total Hcy (tHcy). In healthy volunteers, it contributes only 0.14%-0.28% of tHcy, has a half-life of 1 h, and is below the detection limit in approximately one half of volunteers (1).

Paraoxonase 1 (PON1) is a hydrolase associated with HDL that is thought to degrade lipid peroxides and HTL (2). Decreased PON1 activity has been associated with atherosclerosis (3). Hepatic expression of the PON1 gene is down-regulated in hyperhomocysteinemic mice (4); it is plausible, therefore, that the proatherogenic effects of Hcy may involve diminished serum PON1 activity, leading to impaired antioxidant function and decreased capacity to degrade HTL. In support of this hypothesis, an inverse relationship between PON1 and Hcy in hospital patients was reported recently (5). However, this report did not provide any information regarding patient type or the influence of confounding factors. We investigated the association between tHcy and PON1 in a general population, correcting for the effects of the following confounding factors: HDL concentration, body mass index, sex, and [PON1.sub.192], [PON1.sub.55], and [PON1.sub.-107], genotypes.

We studied a representative sample (200 women and 209 men; age range, 19-75 years) of the general population. Details of this population have been reported previously (6). Serum PON1 activity and concentration, HDL concentration, and PON1 polymorphisms were determined as described previously (6-8). We measured tHcy by fluorescence polarization immunoassay (Abbott Laboratories) and used log-transformations of tHcy and PON1 to approach normality for statistical tests requiring gaussian distributions. We determined the Spearman correlation coefficients for the bivariate associations between tHcy and PON1 and used the Student unpaired t-test to assess differences in mean PON1 activity and concentration in individuals in the highest tHcy tertile compared with the rest of the population. We used multiple linear regression analysis with adjustment for confounding factors to assess the relationships between these variables. Results are presented as the mean (geometric mean in the case of Hcy) and 95% confidence interval (95% CI).

We observed the following means (95% CI) in our population: tHcy, 8.9 (8.7-9.2) [micro]mol/L; HDL, 1.53 (1.49-1.57) mmol/L; PON1 activity, 411 (396-426) U/L; PON1 concentration, 96.5 (88.8-104.2) mg/L.

Bivariate analysis showed no significant relationship between tHcy and PON1 activity (r = -0.089; P = 0.07) or between tHcy and PON1 concentration (r = 0.075; P = 0.15). The correlation was unchanged after exclusion of 12 participants with tHcy greater than the mean + 2 SD (r = -0.089; P = 0.08). However, persons in the highest tHcy tertile had significantly lower PON1 activity than the remaining participants [388 (362-414) vs 422 (404-441) U/L; P <0.05]. There was no significant difference between PON1 concentrations observed according to tHcy tertile [92 (80-103) vs 99 (89-109) mg/ L]. The multiple linear regression models are summarized in Table 1. tHcy had no significant or independent influence on either PON1 activity or concentration.

Thus, although PON1 activity was lower in the highest tHcy tertile of our participants, the association between tHcy and PON1 activity was not significant when we adjusted for confounders, especially the PON192 genotype. We consider it essential, therefore, to adjust for PON1 genotypes when investigating the influences of other factors on PON1. Importantly, we studied a general population, whereas the previous report (5) was performed with hospital patients, in whom several diseases could have affected the results. Our population clearly had a substantially lower mean tHcy (8.9 [micro]mol/L) than that of the hospital patients in the previous report (~15.5 [micro]mol/L) (5). Moreover, we measured the activity of PON1 with paraoxon as substrate, whereas the previous study (5) used phenylacetate as a substrate. From our study, which provides information regarding the relationship between tHcy concentrations and PON1 in a general population, we conclude that a negative effect of tHcy on PON1 activity might be seen only in situations with increased tHcy. This work was supported by Grants 02/0430 and 00/0954 from Fondo de Investigacion Sanitaria and by the Red de Centros de Metabolismo y Nutricion (C03/08). Dr. Ferre is a researcher from the Juan de la Cierva program (Madrid, Spain).

DOI: 10.1373/clinchem.2005.064212


(1.) Chwatko G, Jakubowski H. Homocysteine-thiolactone in human plasma. Anal Biochem 2005; 337:271-7.

(2.) Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. J Biol Chem 2000;275:3957-62.

(3.) Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration, and genotype in cardiovascular disease. Curr Opin Lipidol 2004;15:399-404.

(4.) Janel N, Robert K, Chabert C, Ledru A, Gouedard C, Barouki R, et al. Mouse liver paraoxonase-1 gene expression is downregulated in hyperhomocysteinemia. Thromb Haemost 2004;92: 221-2.

(5.) Janel N, Robert K, Demuth K, Gouedard C, Barouki R, Chasse JF, et al. Inverse relationship between phenylacetate hydrolase activity of the serum PONI protein and homocysteinemia in humans. Thromb Haemost 2005;93:182-3.

(6.) Ferre N, Camps J, Fernandez-Ballart J, Arija V. Murphy MM, Ceruelo S, et al. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem 2003;49:1491-7.

(7.) Ferre N, Camps J, Marsillach J, Mackness B, Mackness M, Coll B, et al. Comparison of paraoxonase 1 measurements in serum and in lithium-heparin-anticoagulated plasma samples. Clin Chem 2005;51:922-3.

(8.) Ferre N, Marsillach J, Camps J, Rull A, Coll B, Tous M, et al. Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. Clin Chim Acta 2005;361:20610.

Michelle M. Murphy, [1] Judit Marsillach, [2] Jordi Camps, [2] * Joan Fernandez-Ballart, [1] Bharti Mackness, [3] Michael Mackness, [3] Natalia Ferre, [4] Jorge Joven [2]

[1] Unitat de Medicina Preventiva i Salut Publica Facultat de Medicina i Ciencies de la Salut Universitat Rovira i Virgili Institut de Recerca en Ciencies de la Salut Reus, Spain

[2] Centre de Recerca Biomedica Hospital Universitari de Sant Joan Institut de Recerca en Ciencies de la Salut Reus, Spain

[3] Department of Medicine Manchester Royal Infirmary Manchester, United Kingdom

[4] DNA Unit Institut d'Investigacions Biomediques August Pi i Sunyer Hospital Clinic Barcelona, Spain

* Address correspondence to this author at: C. Sant Joan s/n, 43201-Reus, Catalunya, Spain. Fax 34-977-312569; email
Table 1. Effect of tHcy and other confounding factors on PON1
activity and concentration. (a) Percentage change

 PON1 activity PON1 concentration

5 [micro]mol/L increase in tHcy -2.3 -3.1
1 mmol/L increase in HDL 16.9 (b) -16 (c)
[PON.sub.192] RR genotype 77 (b) -2
[PON.sub.54] MM genotype -33 (b) 5.7
[PON.sub.-107] TT genotype <-6 (b) -2
F 48.475 1.002
P <0.001 NS

(a) Multiple linear regression analysis. Models are adjusted for body
mass index and sex. The table shows the percentage changes in
PON1 activity and concentration for the indicated predictor. In the
case of PON1 polymorphisms, the table shows the effect of being

(b) P 0.001.

(c) P 0.05.

(d) NS, not significant.
COPYRIGHT 2006 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Letters
Author:Murphy, Michelle M.; Marsillach, Judit; Camps, Jordi; Fernandez-Ballart, Joan; Mackness, Bharti; Mac
Publication:Clinical Chemistry
Article Type:Letter to the editor
Date:Apr 1, 2006
Previous Article:Multiplex PCR assay for the identification and differentiation of all Brucella species and the vaccine strains Brucella abortus S19 and RB51 and...
Next Article:Tumor M2 pyruvate kinase as a stool marker for colorectal cancer: stability at room temperature and implications for application in the screening...

Related Articles
Increased influence of genetic variation on PON1 activity in neonates.
Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns.
Lead exposure is associated with decreased serum paraoxonase 1 (PON1) activity and genotypes.
Accuracy and biological variation of human serum paraoxonase I activity and polymorphism (Q192R) by kinetic enzyme assay.
Factors associated with paraoxonase genotypes and activity in a diverse, young, healthy population: the Coronary Artery Risk Development in Young...
Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate.
Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage.
Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population.
Racial differences in paraoxonase-1 (PON1): a factor in the health of southerners?
Critical confluence: gene variants, insecticide exposure may increase childhood brain tumor risk.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters